Home > Insider Trading > Filing (0001209191-14-077800)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1454189	Auspex Pharmaceuticals Inc.	ASPX	Pharmaceutical Preparations (2834)	954862842

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1440127	A David Stamler	3333 N. Torrey Pines Court Suite 400 La Jolla CA 92037	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-12-22	2,660	$0.90	3,643	No	4	M	Direct
Common Stock	Disposition	2014-12-22	1,560	$53.28	2,083	No	4	S	Direct
Common Stock	Disposition	2014-12-22	1,100	$53.92	983	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2014-12-22	2,660	$0.00	2,660	$0.90

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
28,274		2021-03-10	No	4	M	Direct

Footnotes

Includes 591 shares purchased through the Company's 2014 Employee Stock Purchase Plan ("ESPP") on May 20, 2014, and 392 shares purchased through the ESPP on November 20, 2014.
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 23, 2014.
This transaction was executed in multiple trades at prices ranging from a low of $52.80 to a high of $53.64. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from a low of $53.71 to a high of $54.065. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The original option grant to purchase 30,934 shares of common stock (split-adjusted) is subject to monthly vesting over a four-year period beginning on February 15, 2011.